CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

ERBB2 (HER2) activating mutation

Gene: ERBB2 · Type: mutation

Indications: Non-small cell lung cancer, Breast cancer

SensitivityResistanceCIViC Context

FDA Sensitivity Assertions

DrugIndicationRecommendationFDA SourceLink
Fam-trastuzumab deruxtecanNon-small cell lung cancer, Breast cancerINDICATED
FDA Label
Label
NeratinibNon-small cell lung cancer, Breast cancerINDICATED
FDA Label
Label